An intranasal formulation containing the hydrochloride salt form of the indazole derivative granisetron, a selective serotonin (5-hydroxytryptamine; 5-HT) receptor antagonist, with antinauseant and antiemetic activities. Upon administration to the nostril, granisetron selectively binds to and inhibits 5-HT subtype 3 receptors (5-HT3R) located peripherally on vagus nerve terminals and centrally in the chemoreceptor trigger zone (CTZ) of the area postrema, which may result in suppression of chemotherapy-induced nausea and vomiting (CINV).